Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
- 31 May 1996
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 39 (2-3), 139-143
- https://doi.org/10.1016/0168-3659(95)00147-6
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine*Clinical Pharmacology & Therapeutics, 1995
- Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapyMolecular Carcinogenesis, 1995
- The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*Clinical Pharmacology & Therapeutics, 1995
- Individual Variation in First-Pass MetabolismClinical Pharmacokinetics, 1993
- Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme inductionClinical Pharmacology & Therapeutics, 1992
- Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.JCI Insight, 1992
- First-pass metabolism of cyclosporin by the gutThe Lancet, 1991
- Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.JCI Insight, 1987